Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
Open Access
- 6 February 2021
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 27 (2), 321-328
- https://doi.org/10.1111/hae.14253
Abstract
Introduction/Aim Eptacog beta is a recombinant activated human factor VII approved to treat and control bleeding in haemophilia A and B patients with inhibitors. Emicizumab is a factor VIIIa mimetic antibody approved for prophylactic treatment of haemophilia A with and without inhibitors (HAI and HA, respectively). Inhibitor patients treated with emicizumab should expect breakthrough bleeding that requires bypassing agent treatment to restore haemostasis. The aim of this study is to quantify the in vitro thrombin generation induced by the addition of eptacog beta to HAI and HA plasma containing emicizumab. Methods Thrombin generation assays were performed using HAI and HA plasma. Thrombin generation parameters were examined using a fixed effects model with inhibitor titre, eptacog beta concentration and emicizumab concentration as main effects, and eptacog beta concentration with inhibitor and emicizumab concentration with inhibitor as interaction effects. Results A significant increase in peak thrombin, ETP and velocity was observed when combinations of eptacog beta (0, 1, 2 or 5 µg/ml) and emicizumab (0, 50 or 100 µg/ml) were evaluated in HA and HAI plasma; the effect remained below that observed in Normal Plasma (NP). A small shortening of lag time below that of NP was observed. Conclusions Eptacog beta and emicizumab induced thrombin generation in haemophilia A plasma (with and without inhibitors) with the thrombin generation parameters remaining below those of normal plasma. These data provide in vitro proof of concept supporting the concept of use of eptacog beta for the treatment and control of breakthrough bleeding in patients on emicizumab prophylaxis.Keywords
This publication has 20 references indexed in Scilit:
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsThe New England Journal of Medicine, 2017
- PERSEPT 1: a phase 3 trial of activated eptacog beta for on‐demand treatment of haemophilia inhibitor‐related bleedingHaemophilia, 2017
- Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its actionBlood Advances, 2017
- Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbitsHaemophilia, 2017
- Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophiliaHaemophilia, 2016
- The thrombin generation assay distinguishes inhibitor from non‐inhibitor patients with severe haemophilia AHaemophilia, 2016
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor ActivityPLOS ONE, 2013
- Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipidsBlood, 2012
- Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsJournal of Thrombosis and Haemostasis, 2010
- Thrombin Generation in Plasma: Its Assessment Via the Endogenous Thrombin PotentialThrombosis and Haemostasis, 1995